At the AACR symposium “Expanding and Translating Cancer Synthetic Vulnerabilities,” Faith C. Fowler et al. reported that through continuous treatment of MSI-H cell lines with HRO761 and two novel WRN inhibitors, multiple point mutations in the WRN helicase domain were identified. These mutations directly blocked inhibitor binding and drove resistance mechanisms, highlighting the urgency of developing second-generation WRN inhibitors capable of overcoming resistance, along with corresponding resistant cell models. To address this, we independently established the WRN-MutCell platform, which leverages CRISPR/Cas9 technology to precisely introduce multiple resistance mutations at endogenous WRN gene loci, aiming to provide robust support for structural optimization and functional evaluation of second-generation WRN inhibitors.
Werner syndrome protein (WRN) belongs to the RecQ family of DNA helicases and is involved in replication fork restart, genome stability maintenance, and telomere protection. In MSI-H tumors, DNA secondary structures accumulate due to mismatch repair deficiency, creating a “synthetic lethal” dependence on WRN helicase activity. WRN inhibition can selectively induce death in MSI-H cells.
Biological Functions of WRN
- Replication Fork Maintenance: WRN promotes replication fork restart through its ATPase/helicase activity in BRCA2-deficient cells and limits MRE11-mediated fork degradation, ensuring genomic integrity.
- Helicase Core Structure: The WRN helicase core contains a winged-helix (WH) domain and an ATP-binding pocket. Residue I852 is located in a key α-helix region; the I852F mutation can alter enzyme activity and reproduce a resistance phenotype.
- Therapeutic Relevance: WRN shows synthetic lethal dependence in various MSI-H solid tumors (colorectal cancer, gastric adenocarcinoma, endometrial cancer, etc.), making it a novel target for precision therapy. WRN loss or inhibition can significantly sensitize MSI-H tumors to DNA damage response drugs (e.g., PARP inhibitors), providing a rationale for combination therapies.
Current WRN Inhibitor Landscape
- HRO761 (Novartis): The first non-covalent WRN inhibitor in Phase I clinical trials (NCT05838768), targeting MSI-H colorectal cancer and other MSI solid tumors.
- NTX-452 (Nimbus Therapeutics): A novel non-covalent WRN inhibitor, demonstrating potent synthetic lethality in preclinical models, with clinical trials planned for early 2025.
- VVD-133214: A covalent, fully allosteric WRN inhibitor discovered via chemical proteomics, now at clinical candidate stage.
- RO7589831: WRN inhibitor clinical study supported by the US NCI, focusing on various MSI-H tumor types.
The HCT116-WRN-KI cell line precisely models MSI-H tumor dependence on WRN synthetic lethality and can be used to:
- Identify WRN-related resistance mechanisms
- Screen and evaluate novel WRN inhibitors
- Optimize combination strategies with other DNA damage drugs
WRN‑MutCell Platform Products and Services
HCT116-WRN-mut-KI In Vitro Validation Data Image
HCT116-WRN-mut-KI Cell Line Series Constructed:
- HCT116-WRN-G729D-KI
- HCT116-WRN-G729D-I852F-KI
- HCT116-WRN-1577-1G>C-KI
- HCT116-WRN-F730L-KI
References:
- Ferretti S, Hamon J, de Kanter R, Scheufler C, Andraos-Rey R, Barbe S, et al. Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers. Nature. 2024.
- Chan EM, Shibue T, McFarland JM, Gaeta B, Ghandi M, Dumont N, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. 2019 Apr;568(7753):551–556.
- Morales-Juarez DA, Jackson SP. Clinical prospects of WRN inhibition as a treatment for MSI tumours. NPJ Precision Oncology. 2022;6:85
